Overview

An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors

Status:
Completed
Trial end date:
2020-07-24
Target enrollment:
Participant gender:
Summary
The purpose of the study was to assess the use of Multikinase Inhibitors (MKIs) in the treatment of patients with a progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine (RAI) who do not have any symptoms.
Details
Lead Sponsor:
Bayer
Treatments:
Iodine
Sorafenib